Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

RAM V Nampoothiri, MDDM MRCP (UK), Carol Chen, Zeyad Al-Shaibani, MD, Ivan Pasic, MDPhD, Arjun Law, MD, Wilson Lam, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD, Santhosh Thyagu, MDDM

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142982

Published: 2020

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-141790

Published: 2020

Journal Articles

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Siddharth Jayant Kunte, MD, Lisa Rybicki, MS, Auro Viswabandya, MD, Asad Bashey, MD PhD, Madiha Iqbal, MBBS, Michael R. Grunwald, MD, Bhagirathbhai Dholaria, MBBS, Hany Elmariah, MDMS, Michael Ozga, MD, Anurag K. Singh, MD, Sameem Abedin, MD, Vikas Gupta, MD FRCP, FRCPath, Amy E. DeZern, MD, Richard J. Jones, MD, Aaron T. Gerds, MDMS, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-136622

Published: 2020

Journal Articles

Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Swe Mar Linn, MBBS, Omar Abduljalil, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, RAM V Nampoothiri, MDDM MRCP (UK), Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Fotios Michelis, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattson, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142182

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: Updated Results from a Systematic Review

Lianne E Rotin, MDPhD, Auro Viswabandya, MD, Rajat Kumar, MD, Kevin H.M. Kuo, MDMSc,FRCPC

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141309

Published: 2020

Journal Articles

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

RAM V Nampoothiri, MDDM MRCP (UK), Lina Ho, Cassandra McEwan, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-142302

Published: 2020

Journal Articles

Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission

Muhned Alhumaid, MD, Georgina S. Daher-Reyes, MD, Arjun Law, MD, Auro Viswabandya, MD, Armin Gerbitz, MD, Fotios Michelis, MD PhD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Ivan Pasic, MDPhD, Rajat Kumar, MD, Wilson Lam, MD, Zeyad Al-Shaibani, MD, Hassan Sibai, MBBS, Dennis Dong Hwan Kim, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136122

Published: 2020

Journal Articles

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

RAM V Nampoothiri, Arjun Law, MD, Wilson Lam, MD, Zeyad Al-Shaibani, David Loach, MD, Carol Chen, Dennis Dong Hwan Kim, MD PhD, Fotios V. Michelis, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MD

Blood (2019) 134 (Supplement_1): 5737.

https://doi.org/10.1182/blood-2019-128445

Published: 2019

Journal Articles

The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Dennis Dong Hwan Kim, MD, Taehyung Kim, MSc, Tracy Murphy, MDFRCP,FRCPath, Steven M Chan, MD PhD, Mark D. Minden, MD PhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MDDM, Fotios V. Michelis, MD PhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Jean C.Y. Wang, MD

Blood (2019) 134 (Supplement_1): 3299.

https://doi.org/10.1182/blood-2019-128281

Published: 2019

Journal Articles

Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study

Sunu Cyriac, MD MBBS, Auro Viswabandya, MD, Zeyad Al-Shaibani, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Wilson Lam, MD, Dennis Dong Hwan Kim, MD, Arjun Law, MDDM, Tobias Gedde-Dahl, MD PhD, Yngvar Floisand, MD PhD, Mats Remberger, PhD, Jonas Mattsson, MD, Fotios V. Michelis, MD PhD

Blood (2019) 134 (Supplement_1): 3341.

https://doi.org/10.1182/blood-2019-125941

Published: 2019

Journal Articles

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Zeyad Al-Shaibani, MD, Eshrak AL-Shaibani, MD, Mats Remberger, PhD, Wilson Lam, MD, Arjun Law, MD, Fotios V. Michelis, MD PhD, Auro Viswabandya, MD, Dennis Dong Hwan Kim, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Rajat Kumar, MD

Blood (2019) 134 (Supplement_1): 2046.

https://doi.org/10.1182/blood-2019-124208

Published: 2019

Journal Articles

Impact of Hematopoeitic Cell Transplantation-Co-Morbidity Index (HCT-CI) and Its Individual Components on Allogeneic Transplant Outcomes

Sunu Cyriac, MD MBBS, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD, Rajat Kumar, MD, Wilson Lam, MD, Arjun Law, MDDM, Zeyad Al-Shaibani, MD, Jonas Mattsson, MD, Fotios V. Michelis, MD PhD

Blood (2019) 134 (Supplement_1): 5722.

https://doi.org/10.1182/blood-2019-127654

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: A Systematic Review

Lianne E Rotin, MD PhD, Auro Viswabandya, MD, Rajat Kumar, MD, Kevin H. M. Kuo, MDMSc,FRCPC

Blood (2019) 134 (Supplement_1): 4714.

https://doi.org/10.1182/blood-2019-124989

Published: 2019

Journal Articles

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

Shruti Prem Sudha, MD DM, Eshetu G Atenafu, M.Sc., P.Stat, Queralt Salas Gay, MD, Zoe Evans, Zeyad Al-Shaibani, MD, David Loach, MD, Arjun Law, MDDM, Wilson Lam, MD, Santhosh Thyagu, MD DM, Fotios V. Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Auro Viswabandya, MD DM

Blood (2018) 132 (Supplement 1): 4569.

https://doi.org/10.1182/blood-2018-99-111955

Published: 2018

Journal Articles

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Warren Fingrut, BSc, MD, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2018) 132 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2018-99-113938

Published: 2018

Journal Articles

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Maria Rhida Bautista, MD FRACP, FRCPA, Arjun Law, MD DM, Wilson Lam, MD, Fotios V. Michelis, MD PhD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Rajat Kumar, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3403.

https://doi.org/10.1182/blood-2018-99-119472

Published: 2018

Journal Articles

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Mohammed A. Marei, Eshetu G Atenafu, MSc, P.Stat, Arjun Law, MD DM, Wilson Lam, MD, Rajat Kumar, MD, Santhosh Thyagu, MD DM, Auro Viswabandya, MD DM, Dennis Dong Hwan Kim, MD, Jeff H. Lipton, MD PhD, Hans A. Messner, MD PhD, Fotios V. Michelis, MD PhD

Blood (2018) 132 (Supplement 1): 4670.

https://doi.org/10.1182/blood-2018-99-113884

Published: 2018

Journal Articles

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 5781.

https://doi.org/10.1182/blood.V128.22.5781.5781

Published: 2016

Journal Articles

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Hassan A. Aljasem, MBBS, MD, Hans A. Messner, MD PhD, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Auro Viswabandya, MD DM, Santhosh Thyagu, MBBS, MD DM, Uday Deotare, MD DM, Fotios V. Michelis, MD PhD

Blood (2016) 128 (22): 5838.

https://doi.org/10.1182/blood.V128.22.5838.5838

Published: 2016

Journal Articles

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Uday Deotare, MD DM, David Loach, MD, Fotios V. Michelis, MD PhD, Dennis D. Kim, MD PhD, Santhosh Thyagu, MBBS, MD DM, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Auro Viswabandya, MD DM

Blood (2016) 128 (22): 3430.

https://doi.org/10.1182/blood.V128.22.3430.3430

Published: 2016

NARROW

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience

Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: Updated Results from a Systematic Review

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission

Predictors of Outcomes in Adult Patients with Therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - Twenty Year Experience from a Tertiary Care Centre

The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Patient Age and Donor HLA Matching Can Stratify Allogeneic Hematopoietic Cell Transplantation (HCT) Patients into Prognostic Groups: A Collaborative Study

Risk Factors for Primary and Secondary Graft Failure in Allogenic Hematopoietic Cell Transplantation: A Single Center Study

Impact of Hematopoeitic Cell Transplantation-Co-Morbidity Index (HCT-CI) and Its Individual Components on Allogeneic Transplant Outcomes

Allogeneic Hematopoietic Stem Cell Transplant Versus Gene Therapy in Sickle Cell Disease: A Systematic Review

Combination of ATG and Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Peripheral Blood Stem Cell Transplants for High-Risk Hematological Malignancies- a Single Centre Experience

High Post-Transplant Ferritin Level Associates with Adverse Survival and Higher Mortality Rate following Allogeneic Hematopoietic Stem Cell Transplant, whereas Pre-Transplant Ferritin Level Does Not

Comprehensive Analysis of Systemic Immunosuppression (SIS) Duration after Allogeneic Hematopoietic Stem Cell Transplant: Risk Score Model Provides Stratification of Patients According to Probability of SIS Discontinuation

Comparison of the Impact of Pre-Transplant Co-Morbidity Scores on Allogeneic Hematopoietic Stem Cell Transplant Outcomes

Effective Strategy to Prevent Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Hematopoietic Cell Transplants By Using a Combination of Anti-Thymocyte Globulin (ATG), Post-Transplant Cyclophosphamide and Cyclosporine

Outcome Following Second Allogeneic Hematopoietic Cell Transplantation: A Single Centre Experience

Post Transplant Cyclophosphamide (PTCy) with Anti-Thymocyte Globulin (ATG) Effectively Reduces the Severe (Grade III-IV) Acute Graft-Versus-Host Disease (GVHD) When Compared to ATG Alone in Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplants

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only